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Abstract
Background: The disturbance of zinc homeostasis featured with a significant decrease of cellular
zinc level was well documented to associate with the development and progression of human
prostate malignancy. We have previously reported that zinc treatment induces prostate malignant
cell apoptosis through mitochondrial pathway. Metallothionein (MT) is a major receptor/donor of
zinc in the cells. However, the studies on the expression of MT in association with the prostate
pathological and malignant status are very limited, and the zinc regulation of MT isoform expression
in prostate cells remains elusive. The goals of this study were to define the expression of
endogenous MTs, the isoforms of MT 1, 2, 3 at both messenger ribonucleic acid (mRNA) and
protein levels; and to investigate the zinc effect on MT expression in normal prostate, benign
prostatic hyperplasia (BPH) and malignant PC-3 cells, and in relevant human tissues. Cellular MT
proteins were detected by immunohistochemistry, fluorescence staining and Western blot analysis;
reverse transcription polymerase chain reaction (RT-PCR) was used to determine the MT isoform-
specific mRNAs.
Results: Our results demonstrated a significant suppression of endogenous levels of MT1/2 in
malignant PC-3 cells (95% reduction compared to the normal prostate cells) and in human
adenocarcinoma tissues (73% MT1/2 negative). A moderate reduction of MT1/2 expression was
observed in BPH. Zinc treatment remarkably induced MT1/2 expression in PC-3 and BPH cells,
which was accordant with the restored cellular zinc level. MT 3, as a growth inhibitory factor, was
detected and up-regulated by zinc mainly in BPH cells.
Conclusion: This study provided evidence of the association of attenuated MT1/2 with prostate
tumor progression, and the zinc induction of MT1/2 expression resulting in cellular zinc
restoration. The results suggest the potential of MT1/2 as a candidate biomarker for prostate
cancer and the utilization of zinc in prostate cancer prevention and treatment.
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Background
Zinc is an essential element involved in many cellular
functions and is required by approximately 300 enzymes
for their biological activities [1]. In humans, deficiency of
zinc might inhibit growth [2], but it is also closely related
to increased risk of certain malignant tumors [3,4]. Nor-
mal prostate contains the highest zinc level, but a dra-
matic decrease of cellular zinc (60–70% loss) was found
in malignant prostate cells [5]. We have demonstrated
that zinc exposure induces apoptosis in malignant pros-
tate PC-3 and benign hyperplasia prostate (BPH) cells, but
not in normal prostate HPR-1 cells [6,7]. Despite few
studies on the relationship of zinc accumulation and zinc-
induced prostatic cell apoptosis [8-10], the mechanisms
of the disturbance of zinc homeostasis and zinc restora-
tion in relation to pathogenesis and malignancy of pros-
tate tissues remain unclear.
Cellular zinc homeostasis is modulated by many factors
such as zinc transporters (ZnTs and ZIPs) and metal-
lothioneins (MTs), which are involved in the aspects of
zinc transport, trafficking, and signals [11]. Among these
factors, MTs are of low molecular weight (~6 kd); mole-
cules and the cysteine-rich motifs in α and β domain are
responsible for their zinc-binding property, hence, the Zn-
MT-thionein conjugated pair functions as a receptor/
donor for other zinc-related proteins [12]. MTs are ubiq-
uitously expressed in most cells and tissues and play
important roles in many biological processes such as
metal ion homeostasis and detoxification, protection of
cells from the damage caused by oxidative stress, cell pro-
liferation and apoptosis, and in some aspects of the carci-
nogenic process [13,14].
MT genes belong to a super family with characteristics
common to equine MT, first isolated half a century ago
[15,16]. Since then, four isoforms (MTs 1, 2, 3, and 4)
were identified [17]; among them, MTs 1 and 2 are the
major isoforms expressed in most adult mammalian tis-
sues. MT 3 was originally found exclusively in the normal
human brain as growth inhibitor factor [18], and lately,
the expression of MT 3 was further identified in kidney,
breast, pancreas, intestine, bladder, and prostate cancer
[19,20]. MT 4 expression was reported in the stratified
squamous epithelium and has an important role in cell
differentiation [21].
The zinc regulation of MT gene transcription was through
metal response elements (MREs), which are present in
multiple copies within the proximal promoters of MT
genes [22]. MREs seem to be MT isoform-dependant and
cell-type specific. In prostate cells, high concentration of
zinc (100 μM)-induced MT1/2 expression was studied in
malignant PC-3 cells [13,23]. However, the information
regarding zinc regulation of MT1/2 in normal and BPH
cells is very limited, whereas contradictory observations of
this in human prostate tissues were reported. In addition
to MT1/2, several MREs on the promoter region of MT 3
gene were also identified; however, the effect of zinc on
MT 3 expression has not been clarified [24]. To date, ques-
tions of whether MT 3 is expressed in human prostate and
whether such expression is regulated by zinc associated
with its growth-inhibitory role remain unclear and need
to be studied.
In addition to the previous findings from different inves-
tigations, this study for the first time provided new evi-
dence on zinc regulation of MT gene expression and
elucidated the relationship between the gene expression
and the cellular zinc homeostasis in relation to the patho-
genesis status of the prostate tissues.
Results
Differential expression of endogenous MT1/2 in normal, 
benign hyperplasia, and malignant prostate cells 
correlates to the cellular zinc levels
To ascertain the relationship between zinc homeostasis
and MT1/2 gene expression in prostate tumorigenesis, the
cellular zinc accumulation and the endogenous MT1/2
protein levels were detected in normal HPR-1, BPH, and
malignant PC-3 cells. As shown in Fig. 1, higher endog-
enous cellular zinc was found in HPR-1 cells followed by
BPH, and the lowest zinc level was detected in PC-3 cells.
After the zinc treatment, a significant gaining of the cellu-
Cellular zinc accumulation in human prostate cells Figure 1
Cellular zinc accumulation in human prostate cells. 
Human prostatic HPR-1, BPH, and PC-3 cells were treated 
with (grey bars) or without (black bars) zinc (15 μM) in 
serum/pituitary extracts-free medium for 3 h. Thirty micro-
liters of each cellular sample (200 mg of protein) were placed 
in a 96-well plate and the fluorescence of zinc labeled by TSQ 
was detected with a Microplate Reader (Fluoroskan Ascent, 
Labsystems).Molecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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lar zinc was observed in both BPH and PC-3 cells with 1.7-
fold and 3.3-fold increase, respectively. In contrast, the
zinc level in HPR-1 cells was modestly enhanced (<0.6-
fold). The cellular endogenous MT1/2 proteins in three
cell lines were further evaluated by Western blot analyses
(Fig. 2). The results showed that the highest endogenous
level of MT1/2 was detected in HPR-1 cells, while PC-3
cells appeared to have the lowest endogenous MT1/2,
only about 5% of that found in HPR-1. The MT1/2 in BPH
cells was higher than in PC-3 cells, but still much less,
about 25% of the amount found in HPR-1 cells. Appar-
ently, MT1/2 in HPR-1 and BPH is significantly higher
than in PC-3 cells; however, no significant difference of
MT 1/2 between BPH and PC-3 cells was detected.
The cellular distribution of MT 1/2 was studied by using
immunofluorescence staining (IFS) shown in Fig. 3. A
strong fluorescence intensity of MT1/2 signals was identi-
fied in HPR-1 cells, while a much weaker immunoreactiv-
ity was observed in BPH and PC-3 cells. From the data of
IFS it was further evident that MT1/2 expression displayed
a cell-type specific pattern in the prostate cells. Although
the cytoplasmic and nuclear localization of MT1/2 was
observed in all three cell lines, a higher ratio of nuclear
MT1/2 versus cytoplasmic distribution appeared only in
HPR-1 cells. The specificity of the MT1/2 signals was con-
firmed in the negative controls in which only the second-
ary antibody was applied (top panels of Fig. 3).
The zinc induction of MT1/2 expression is cell-type specific 
in prostate cells
As we reported above, the levels of cellular zinc were cor-
related to the endogenous MT1/2 expression, and zinc res-
toration was higher in BPH and PC-3 cells than in HPR-1
cells (Fig. 1). To extend this important relationship, the
effect of zinc on the induction of MT1/2 was investigated
and a time-course study of zinc-induced MT1/2 was con-
ducted with three cell lines (Fig. 4). The results of Western
blot analyses revealed that zinc exposure (1 μg/ml) of
BPH and PC-3 cells resulted in a significant increase in the
MT1/2 determined early, at 6 h, by about 2.8-fold and 4-
fold compared to the controls, respectively. This distinct
induction effect of zinc on MT1/2 was continuously
observed up to 24 h in both BPH and PC-3 cells. In con-
trast, in HPR-1 cells only a slight increase of MT1/2 expres-
sion, with no significant difference to the controls, was
detected after 12 h of zinc treatment. The results demon-
strated a dynamic association of cellular zinc and MT1/2
expression with a cell-type specific property in prostate
cells.
Effect of zinc on the expression of MT 3 mRNA and 
protein levels in prostate cells
To date, the zinc effect on the transcriptional and transla-
tional level of MT 3 in prostate cells has not yet been
reported. In order to further determine whether zinc regu-
lated MT 3 gene expression, a time-course study of zinc
effect on MT 3 gene transcription was conducted by using
RT-PCR (Fig. 5). The results showed that among three cell
lines, the highest endogenous level of MT 3 mRNA was
identified in BPH cells while a remarkably lower level,
about 25% of that in BPH cells, was detected in PC-3 cells;
and there was only a marginally detectable amount found
in HPR-1 cells (Fig. 5). Most interestingly, zinc treatment
significantly increased MT 3 mRNA in BPH (2-fold) and
PC-3 (3-fold) cells at late time points, at 6 h and 3–6 h,
respectively; however, no zinc induction of MT 3 mRNA
was found in HPR-1 cells.
We further investigated whether MT 3 is expressed at a
functional level and induced by zinc similar to that of the
MT1/2 isoforms (Fig. 4) in prostate cells. Firstly, the
endogenous level of MT 3 protein in three cell lines was
examined, and the signal detected by a specific polyclonal
antibody against MT 3 was only identified in BPH cells
compared to the positive control of the human brain tis-
sue, in which endogenous MT 3 protein is highly
expressed (Fig. 6). In contrast to the MT 3 mRNA levels
obtained from RT-PCR assays, the MT 3 protein was nei-
ther detectable in PC-3 nor in HPR-1 cells. Next, we con-
ducted a time-course study of zinc (15 μM) effect on MT 3
in BPH cells by Western blot analyses (Fig. 7). The expres-
sion of MT 3 displayed a zinc-response pattern, and the
zinc induction of MT 3 was observed in BPH cells with
Detection of endogenous level of MT1/2 proteins in human  HPR-1, BPH, and PC-3 cells Figure 2
Detection of endogenous level of MT1/2 proteins in 
human HPR-1, BPH, and PC-3 cells. The protein 
extracts (30 μg) of each cell line were separated by SDS-
PAGE, and cellular MT1/2 was detected by Western blot 
analysis with rabbit anti-MT1/2 antibody, and β-actin was 
used as an internal control (top panel). The density of specific 
signals of MT1/2 was analyzed and data are presented in 
lower panel. The different letters (a, b, c) represent the sta-
tistical significance (p < 0.05).Molecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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about 3-fold increases after 6 – 12 h of zinc treatment (Fig.
7).
Detection of MT1/2 expression in different human 
prostate tissues by using immunohistochemistry (IHC)
MT1/2 expression in human prostatic tissues obtained
from patients with normal, BPH and/or prostatic adeno-
carcinomas was evaluated by using IHC method. The spe-
cificity of MT1/2 signals identified by IHC staining was
determined by using the negative controls in which only
secondary antibody was applied resulting in no MT1/2
immunoreactive signals (Fig. 8A). The results showed that
various immunoreactivities for MT1/2 were detected in
differential prostate tissues, and the immunoreactivity
was mostly confined to the epithelial cells of prostatic
glands (Fig. 8). In contrast, the stroma cells showed nega-
tive-to-weak immunoreactivity for MT1/2, and the con-
nective tissues appeared to have no reaction to the MT1/2
antibody. In normal prostate tissue (Fig. 8C & D), the dis-
tinct higher intensity of immunostaining was observed in
the nuclei, while the cytoplasm showed an evenly distrib-
uted staining in almost all glandular epithelial cells. The
results showed that in BPH tissue (Fig. 8E &8F) a patchy
MT1/2 staining of epithelial cells was observed, that is,
lacking uniformity of immunoreactivities resulting in
uneven immunostaining intensity among the cells. In
general, the majority of the epithelial cells in BPH tissue
remained immunoreactive to MT1/2, while in some cells
a stronger reaction had occurred than in other cells. A sig-
nificant reduction of the immunostaining intensity was
observed in the malignant adenocarcinomatous glands
(Fig. 8G &8H). Only a few malignant cells appeared to
have had the immunoreaction for MT1/2, whereas the
nuclei and cytoplasm showed a negative reaction to MT1/
2 in most of the malignant cells. A clear evidence of the
cell-type specificity of MT inmmunoreactivity is shown in
Immunofluorescence detection of MT1/2 in HPR-1, BPH, and PC-3 cells Figure 3
Immunofluorescence detection of MT1/2 in HPR-1, BPH, and PC-3 cells. The immunofluorescence statining of MT1/
2 was examined in the cells, HPR-1 (left), BPH (middle), and PC-3 (right). The background of non-specific staining was moni-
tored using the red FLURO-conjugated secondary antibody only indicated as the control (top row), in which the cells were 
also stained with Hoechost 33258 shown the blue-stained nuclei to remark the cells. The differential immunoreactivities of the 
cells to MT1/2 antibody were determined by the intensity of red fluorescence between the cell lines (middle row). The images 
with both MT1/2 and Hoechost nuclear staining (bottom row) were the attempts to detect the cellular distribution of MT1/2. 
The pinkish colour resulted from the merged blue and red colour was observed in some nuclei of HPR-1 cells. All images were 
observed and recorded under the same settings of a fluorescence microscope with the magnification of × 600.Molecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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Fig. 8B, in which no MT1/2 staining was detected in the
field of malignant prostate tissue, while it was positively
detected in adjacent defined BPH tissues in the same field.
A summary of the MT1/2 IHC scores in prostatic adeno-
carcinomas and associated defined BPH tissues collected
from 23 patients is presented in Table 1. The results of the
semi-quantitative scoring showed that the positive MT1/2
immunostaining was found in all BPH tissues, and about
87% of examined BPH tissues appeared to have strong
immunoreactivity for MT1/2 (Scores: ++ & +++). In con-
trast, the negative immunoreactivity for MT1/2 was deter-
mined in most prostatic adenocarcinomatous foci (73%
negative) shown as 13 negative over a total 18 of exam-
ined cases.
Detection of zinc regulation of MT3 gene expression in HPR-1, BPH, and PC-3 cells by RT-PCR Figure 5
Detection of zinc regulation of MT3 gene expression in HPR-1, BPH, and PC-3 cells by RT-PCR. A. Cells were 
treated with or without zinc (20 μM) following 24 h serum-depletion. Zinc effect on MT 3 mRNA levels was evaluated at 1, 3, 
and 6 h of zinc treatment. Total RNA (0.2 μg) was used for 25 μL RT-PCR reaction. The sequences of MT 3 primers are: 
5'CCGTTCACCGCCTCCAG3' (upper); 5'CACCAGCCACACTTCACCACA3' (lower). GAPDH was used as an internal control to nor-
malize MT-3 gene expression. B. The density of specific bands was analyzed and data are presented.
Regulation of MT1/2 protein expression in HPR-1 BPH, and PC-3 cells Figure 4
Regulation of MT1/2 protein expression in HPR-1 BPH, and PC-3 cells. A. The cells were treated with zinc (15 μM) 
for 3, 6, 12, and 24 h, respectively, after 24 h serum-depletion. The protein extracts (30 μg) of each cell line were separated by 
SDS-PAGE, and human MT1/2 was detected by Western blot analysis with rabbit anti-MT1/2 antibody, and β-actin was used as 
an internal control. B. The density of specific bands was analyzed and data are presented.Molecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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Discussion
The findings described above allow us to define the rela-
tionship between the down-regulated MT expression and
the decreased endogenous level of zinc in human prostate
malignant cells and tissues. The disturbance of zinc home-
ostasis in prostate would significantly impair the cellular
metabolism and growth as discussed previously [5,6].
Now, a critical issue could be raised: Does the low level of
cellular zinc lead responsively to a suppressed endog-
enous MT level or does the down-regulated MT expression
result in a significant depletion of cellular zinc underlying
the tumorigenesis of prostate tissues. Most recently, an
important study on the mechanism of MT gene regulation
by metal response element-binding transcription factor-1
(MTF-1) was reported by Dr. R. Tjian's group [25]. In this
study, the robust response of the MT genes to metal was
used as a model; MTF-1, a core facilitating factor, and two
central regulatory factors, transcription factor II D (TFIID)
and mediator (MED), were identified as major players in
modulating the transcriptional response of MT to metal.
The MTF-1 recruits TFIID, which then binds MT promoter
DNA and subsequently activates transcription upon
recruitment of the MED [26]. The appropriate expression
of the endogenous MT genes is achieved only when these
coactivators are balanced. Intriguingly, they found that
the MTF-1 requires different coactivator subunits depend-
ing on the context of the core promoter (the stability of
the multi-subunit coactivator complexes can be compro-
mised by loss of a single subunit), leading to the potential
control of fine-tune transcriptional regulation. We
observed that the endogenous level of MT in the prostate
cells is cell-type specific and that the oncological trend of
Detection of zinc regulation of MT 3 expression in BPH cells  by Western blot analysis Figure 7
Detection of zinc regulation of MT 3 expression in 
BPH cells by Western blot analysis. BPH cells were 
treated with zinc (15 μM) or without zinc (control) for 3, 6, 
12, and 24 h, respectively. The protein extracts (50 μg) of 
samples from each time point were separated by SDS-PAGE, 
and the MT 3 was detected by Western blot analysis (top 
panel) with rabbit anti-MT 3 antibody and β-actin was used as 
an internal control. The density of specific MT 3 signals was 
analyzed and data are shown on the lower panel. The experi-
ment was repeated at least thrice.
Endogenous level of MT 3 protein in HPR-1, BPH, and PC-3  cells Figure 6
Endogenous level of MT 3 protein in HPR-1, BPH, 
and PC-3 cells. The cells were grown to confluence and 
harvested. The protein extracts (50 μg) of each cell line were 
separated by SDS-PAGE, and the MT 3 was detected by 
Western blot analysis with rabbit anti-MT 3 antibody, and β-
actin was used as an internal control (Top panel). The density 
of specific MT 3 signals was analyzed as described in the 
Materials and Methods, and the data are shown on the lower 
panel. The experiment was repeated at least thrice.Molecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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the endogenous MT may be closely related to MTF-1-
involved MT gene regulation.
The alteration of MT1/2 gene expression was not only
found in human prostate, but was also discovered in pri-
mary human hepatocellular carcinomas [27], in which
the suppression of MT1/2 gene expression is mediated
through phosphatidylinositol 3-kinase (PI3K) signaling
pathway by the inactivation of the CCAAT/enhancer bind-
ing protein α (C/EBPα). On the other hand, MTF-1 inter-
acted with C/EBPα as a complex and subsequently
activated MT1/2 gene expression. An early study also indi-
cated that in prostate cancer cell lines the MT1 promoter
activity was suppressed by promoter methylation of cyto-
sine within the CpG dinucleotide region [28]. Besides the
MT promoter methylation, the possibility of dysfunc-
tional interaction of MTF-1 with nuclear factor I (NFI) was
also seriously considered [28]. These findings highlight
insights for future investigations for the regulation of MT
gene expression in association with the prostate zinc
homeostasis and tumorigenesis.
MTs, as zinc donors/receptors, play a key role for zinc-
related proteins and enzymes, which are involved in many
crucial cellular functions including cell metabolism, sign-
aling transduction pathways, and nuclear gene transcrip-
tional regulation. Concordantly with the functions, the
extensive cellular distribution of MT1/2 was observed in
normal prostate HPR-1 cells with the intensity of immun-
ofluorescence staining in the cytosol and even stronger
signals in the nuclei (Fig. 3). However, a substantive
decrease of MT1/2 intensity was displayed in both BPH
and PC-3 cells, which confirmed the result of the Western
Table 1: Summary of the immunorectivity to MT 1/2 in human 
BPH and prostate adenocarcinoma tissues
Case no. Grade* MT1/2 IHC scorea**
BPHb Prostatic carcinoma
1 3 ++ Negative
2 3 ++ Negative
3 1 ++ Negative
42 + + +
5 3 ++ Negative
6 N/A +++ N/A
7 2 ++ Negative
8 N/A ++ N/A
9 1 ++ Negative
10 3 ++ Negative
11 2 ++ Negative
12 3 ++ Negative
13 2 ++ Negative
14 2 ++ Negative
15 3 + Negative
16 N/A ++ N/A
17 N/A ++ N/A
18 2 ++ ++
19 2 ++ +
20 N/A + N/A
21 3 ++ Negative
22 2 ++ ++
23 3 + ++
Slides were prepared from formalin fixed paraffin embedded tissues.
* Gleason grade evaluated using WHO standard [41]
a** Semi-quantitative scoring of immunoreactivity was done as follows 
[40]:
Negative, no positive cells; score +, <10% positive cells; score ++, 
10–50% positive cells; score +++, > 50% positive cells
Immunohistochemistry staining of MT 1/2 in human prostate  tissues Figure 8
Immunohistochemistry staining of MT 1/2 in human 
prostate tissues. Normal (C &D) and BPH (E & F) prostate 
tissues demonstrate MT 1/2 immunoreactivity with positive 
and/or patchy intensity in the glandular epithelial cells. The 
malignant tissues (G & H) appear to be negative to MT 1/2 
staining in most of the cells with a few scattered stained cells. 
Control (A) was stained without primary MT 1/2 antibody. 
Immunoreactivity in a mixed tissue (B) of malignancy and 
BPH is indicated by arrows. Magnifications: 200-fold (B, C, E, 
G) and 400-fold (A, D, F, H)Molecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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blot analysis. In extension of previous observations of
high IHC staining in the nuclei of BPH cells [29], we
found that normal HPR-1 cells exhibit much more aggre-
gation of MT1/2 in nuclei, than BPH and PC-3 cells do.
This suggests that the suppression of MT expression and
the alteration of MT distribution in BPH and PC-3 cells
may negatively influence the cellular function.
The results of the suppressed MT1/2 expression in prostate
malignant cells led us to further investigate MT1/2 expres-
sion in human prostatic tissues including the normal,
BPH, and adenocarcinomas. At the present time, only few
studies provided limited information of MT1/2 expres-
sion in human prostate tissues. Among these data, the cor-
relation of the positive IHC staining of MT1/2 and the
adenocarcinoma status was variable ranging from 33%
(15/45) [30], 67% (20/30) [31] to 100% (5/5) [32]; while
some reports indicated that the Gleason grades of the
tumor tissue scoring from low to high reversely corre-
sponded to the intensity of MT1/2 IHC staining [32,33].
In this study, normal and BPH tissues give images of
intensive and/or patchy MT1/2 IHC staining, which are
consistent with some previous observations [30,31,33].
Moreover, we determined the negative and/or weak MT1/
2 IHC staining in the majority of adenocarcinomatous
cells (72%), which is in agreement with one of most
recent reports (67%) [31], while other studies showed
higher staining signals of MT1/2 in prostate malignant tis-
sues, 33% and 0%, respectively [32,33]. The discrepancy
of the IHC staining data may result from the differential
MT1/2 antibodies and the variable staining methods.
Apparently, examining more prostate malignant tissues
with a standard IHC method will provide significant
information of MT1/2 expression, which could be consid-
ered as the candidate gene used for early diagnosis and
gene therapy for prevention and targeting of prostate
caner.
In addition to MT1/2, we have also determined, for the
first time, the zinc regulation of MT 3 expression at both
transcriptional and translational levels in three prostate
cell models. Although the MT 3 was initially thought to be
a neuron-specific MT isoform possessing a neuronal cell
growth inhibitory activity [18,34], in recent years the
demonstration of a wider, non-neural distribution of
human MT 3 [35,36] motivated a study of MT 3 in pros-
tate, in which a variable nature of MT 3 expression was
detected in prostate tissues and cells [37]. Contrary to
expectations based on the previous study [37], we found
that among three cell models, only BPH cells profoundly
express the highest endogenous level of MT 3, which was
also significantly up-regulated by zinc at both mRNA and
protein levels (Figs. 5 and 7). Also, neither normal HPR-1
nor malignant PC-3 cells seem to express essential
amounts of MT 3 or to respond to zinc induction of the
MT 3, thereby suggesting a cell-type specific nature of the
MT 3 gene expression and regulation. The characteristic
inhibitory effect of MT 3 on cell growth was discriminated
by promoting cell necrosis from cell apoptosis in human
proximal tubule cells [38,39]. We have previously demon-
strated that zinc inhibits prostate BPH and PC-3 cells
growth mainly by cell apoptosis through the mitochon-
drial pathway [7]. Now with the recognition of the zinc
effect on MT 3 in BPH cells, it is possible that the role of
MT 3 as a growth inhibitory factor may also involve in
zinc-induced cell death in BPH cells.
Using human prostate cell models, we demonstrated that
zinc treatment, at least in in vitro cell culture system, can
restore the cellular zinc especially in the malignant cells,
in which the endogenous zinc was depleted possibly due
to the down-regulated MT expression through the MTF-1
involved mechanism. In turn, the restored zinc subse-
quently enhances MT gene expression significantly to
secure the physiological and/or pharmacological level of
zinc which will be recruited quickly by the proteins and
enzymes to resume their bioactivities and eventually to
control cell proliferation and/or death. Hence, zinc sup-
plement may serve as a potential approach to modulate
the molecular environment in prostate BPH and malig-
nant cells aiming to enhance their responses to other
chemotherapeutical treatment.
Conclusion
This study provides important new information on zinc
regulation of MT, isoforms 1, 2 and 3, expression in
human prostate cells and tissues. Evidently, MT1/2
expression is significantly down-regulated in BPH, PC-3
cells, and human prostate malignant tissues; and MT 3
expression is a specific characteristic of BPH cells. Zinc res-
toration leads to re-establishing cellular homeostasis of
zinc through up-regulation of MT gene expression, which
may eventually result in resuming the critical selection for
proliferation or death of the cells. The results suggest MT
as a candidate tumor marker for diagnosis, prognosis and
management guidance; and warrant further investigation
of zinc as a potential supplement to benefit the BPH and
prostate cancer treatment.
Methods
Human prostate cell lines and zinc treatment
Three human prostatic cell lines were used in this study:
(a) HPR-1, a cell line derived from normal human pros-
tate epithelial cells (kindly provided by Dr. C. K. Choo,
University of Hong Kong, Hong Kong, China); (b) BPH, a
cell line derived from human benign prostatic hyperplasia
(BPH) tissue (kindly provided by Dr. S. Haywood, Uni-
versity of California, San Francisco); and (c) PC-3, a
human malignant prostate cell line (ATCC, Rockville,Molecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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MD). HPR-1 cells were cultured in keratinocyte medium
supplemented with epidermal growth factor (EGF) (2.5
mg/500 ml) and bovine pituitary extracts (25 mg/500 ml)
(Gibco BRL, Life Technologies, Bethesda, MD). BPH and
PC-3 cells were cultured in RPMI-1640 medium with 5%
and 10% of fetal bovine serum (FBS), respectively. All
mediums were supplemented with penicillin and strepto-
mycin (1 U/ml, Invitrogen), and the cells were main-
tained at 37°C in a humidified incubator with 5% CO2.
The passages of three cell lines were within the range of 5
– 40.
Once the cells grew up to 50–60% confluence of the cul-
ture, the growth mediums were replaced by fresh serum/
supplement-free medium for 24 h to synchronize cell
growth. The cells were then treated with or without zinc
sulfate (15–20 μM) in fresh serum/supplement-free
medium for 0, 1, 3, 6, 12, and 24 h, respectively.
Determination of MT levels by Western blot analyses
Total cellular proteins from the experimental samples
were extracted by radioimmuno- precipitation
assay(RIPA) lysis buffer (Upstate, Lake Placid, NY) con-
taining protease inhibitor (Roche Diagnostics Gmbh,
Mannheim, Germany). The protein extracts (30 ug/lane)
were applied to electrophoresis on an 18% SDS-polyacry-
lamide gel, and then, a transferred poly(vinylidene fluo-
ride) (PVDF) membrane (Millipore, Billerica, MA) was
blocked in 5% nonfat dry milk in phosphate buffered
saline (PBS) containing 0.05% Tween-20 (Sigma, St.
Louis, MO) (PBST) for 1 hr at room temperature followed
by the hybridization to the primary rabbit polyclonal anti-
body against MT1/2 (kindly provided by Dr. P.C. Huang,
JHU), MT 3 (polyclonal antibody, kindly provided by Dr.
G.F. Hu, Harvard University, MA), and β-actin (Sigma, St.
Louis, MO) used as an internal control, respectively, at
4°C overnight. After being washed, membranes were
incubated with corresponding second antibodies and
washed again. The specific binding signals were visualized
by enhanced chemiluminescence's system (Millipore,
Billerica, MA, for MT1/2 and Pierce, Rockford, IL for β-
actin) according to manufacturer's instructions. The target
bands were scanned and quantified with an LKB Ultra
Scan XL laser densitometer (Image Quant, Molecular
Dynamics, Sunnyvale, CA).
Reverse transcription and polymerase chain reaction assay 
(RT-PCR) for MT 3
Total RNA of the cells collected from the experiments was
extracted using Qiagen (Valencia, CA) RNeasy mini kit
according to the manufacturer's protocol. The quality of
RNA was determined by the ratio of 28S/18S ribosomal
RNA and the ratio of 260/280-nm absorbance. Two
microgram of total RNA were used for complementary
deoxyribonucleic acid (cDNA) synthesis with reverse tran-
scriptase (ABI, Foster City, CA) in a total of 20 μl reaction.
Primer sequences used for PCR to detect MT 3 were
5'CCGTTCACCGCCTCCAG  3' (upper) and 5'CAC-
CAGCCACACTTCACCACA 3' (lower). PCR for MT 3 was
conducted with cDNA template (1.0 μl) mixed with 0.8 μl
of 5 μM upstream primer, 0.8 μl of 5 μM downstream
primer, 0.4 μl of 10 mM deoxyribonucleotide triphos-
phate (dNTP), 0.8 μl of 50 mM MgCl2, 2 μl 10× Taq reac-
tion buffer, and 0.08 μl of 5 U platinum Taq (Invitrogen)
in a total of 20 μl reaction. The protocol used for the ther-
mal cycler (PTC-100 MJ Research, Watertown, MA) was
94°C for 4 min, followed by 94°C for 30 s, 68°C for 30 s,
and 72°C for 30 s at a total of 40 cycles, and followed by
a final extension at 72°C for 7 min. Glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) was used as an inter-
nal control to normalize the MT 3 transcript level. Primer
sequences for GAPDH were 5'CCACCCATGGCAAATTC-
CATGGCA  3' (upper) and 5' TCTAGACGGCAGGTCAG-
GTCCACC 3' (lower). The reaction of the PCR for GAPDH
was similar to that for MT 3, except less cDNA template
(0.4 μl) was used. The protocol for the thermal cycler was
94°C for 4 min, followed by 94°C for 30 s, 55°C for 30 s,
and 72°C for 30 s for a total of 35 cycles and followed by
a final extension at 72°C for 7 min. Eight microliter of
each sample was electrophoresed in 1.2% agarose gels
containing ethidium bromide and the target DNA frag-
ments were visualized and quantified using an LKB Ultra
Scan XL laser densitometer (Image Quant, Molecular
Dynamics, Sunnyvale, CA).
Immunofluorescence staining of MT1/2
The cellular distribution of MT1/2 proteins was deter-
mined by immunofluorescence staining in HPR-1, BPH,
and PC-3 cells. The cells were grown on the cover slips
placed in a 12-well plate and the following procedures
were conducted with the cover slips. The cells were fixed
with 4% paraformaldehyde (USB, Cleveland, Ohio) and
permeabilized with 0.25% Triton ×-100 (Sigma, St. Louis,
MO), respectively. For each treatment the cells were incu-
bated with the reagent for 10 min at room temperature
and then washed three times (10 min/each) in PBS. After
1 h incubation with PBS (10% FBS) at room temperature,
the cells were incubated with rabbit polyclonal anti-MT1/
2 antibody (1:500 dilution) in PBS (2% FBS) at 4°C over-
night. The samples were then washed for five times (5
min/each) in PBS containing 0.05% Tween-20 and 1%
BSA (washing buffer). The goat anti-rabbit FLURO-conju-
gated secondary antibody (1:500 dilution) (Invitrogen,
San Francisco, CA) was applied and followed by the same
washing procedure used for the primary antibody hybrid-
ization. For the nuclear staining, the cells were then incu-
bated with Hoechst 33258 (0.2 μg/ml, Molecular Probes,
Eugene, OR) for 10 min at room temperature and then
washed three times in washing buffer. Finally, the cells
were mounted to the slides with aqueous antifadeMolecular Cancer 2008, 7:7 http://www.molecular-cancer.com/content/7/1/7
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medium (Polyscience, Warrington, PA). The MT1/2
immunofluorescence staining of the cells was analyzed
and photographed using a fluorescence microscope
(Nikon eclipse E800).
Determination of cellular zinc
Prostatic cells were grown in 75 cm2 flasks up to 80% con-
fluence of the culture. The cells were treated with or with-
out zinc (15 μM) in fresh serum-free medium for 3 h.
Before harvest, the cells were washed once with 1× PBS
and then washed twice after the collection to remove
extracellular zinc. The cells were resuspended in sucrose
buffer (250 mM sucrose, 20 mM HEPES, pH 7.4) and
homogenized on ice. The nuclei and cell membranes were
separated by centrifugation at 800 g for 10 min. The
supernatants were then centrifuged at 10,000 g for 5 min,
and these supernatants were used as cytosol samples. The
protein concentrations of the samples were measured by
Bradford method. Thirty microliters of each sample (200
μg of protein) were placed in a 96-well plate and mixed
with 60 μl of TSQ buffer, which was composed of 1.9 g of
sodium acetate, 2.9 g of sodium barbital, 1.5 mg of TSQ
(Molecular Probes, Eugene, OR) dissolved in 100 μl of
warmed ethanol, then dH2O was added to 100 ml, pH 10.
The fluorescence of zinc labeled by TSQ was detected by
using a Microplate Reader (Fluoroskan Ascent, Labsys-
tems, Life Sciences International Company, USA) with
excitation of 360 and emission of 495.
Immunohistochemistry (IHC) study in human prostatic 
tissues
Twenty-three prostatic adenocarcinoma cases from archi-
val paraffin embedded tissue blocks obtained from
Pathology Department, Medical University of South Caro-
lina and approved by the Institutional Review Board were
included in this study. Examination of hematoxylin and
eosin (H&E) stained sections revealed adenocarcinomas
in 18 cases, normal prostatic glands in 5 cases, and all
cases (n = 23) harbored BPH glands. The slides were
coded without identification related to the patients.
Immunohistochemistry (IHC) was carried out with rabbit
anti-human/rat MT1/2 antibody (1:125 dilution) in a
Dako cytomation autostainer with a standard protocol for
IHC. Briefly, the samples of prostate were deparaffinized
with heating and xylene incubation. Antigen retrieval was
done by heating in ethylene diamine tetraacetic acid
(EDTA), PH 9.0 buffer (Lab vision, Fremomt, CA) at
99.3°C for 20 min, incubated in 3% hydrogen peroxide,
blocked with 5% skimmed milk for 5 min, incubated with
MT1/2 antibody at room temperature for 30 min, fol-
lowed by incubation with Horseradish peroxidase-labeled
goat anti-rabbit IgG secondary antibody in a dilution of
1:200 for 30 min. Color was developed by incubating
samples with diaminobenzidine (DAB)+chromogin for
10 min followed by Dako DAB enhancer for 5 min.
Hematoxylin was used as counter stain. The specific stain-
ing of MT1/2 in the sections was examined using BX 50
Olympus microscope and the photographs were taken
with attached Olympus DP 70 camera operated with DP
Controller 2.1.1.183 software (Olympus Corporation).
Semi-quantitative scoring of immunoreactivity was repre-
sented as: "negative" denoted no positive MT1/2 stained
cells found; "+" denoted less than 10% of MT1/2 positive
cells; "++" denoted 10–50% of MT1/2 positive cells;
"+++" denoted more than 50% of MT1/2 positive cells
[40]. The Gleason grade correlated to each case was
defined as WHO standard 1–3 scale [41].
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